Virtual Library
Start Your Search
J.S. Eom
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-082 - Diagnostic Value of Survivin-Expressing Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer (ID 811)
09:30 - 09:30 | Author(s): J.S. Eom
- Abstract
Background:
The most widely used circulating tumor cell (CTC) isolation techniques rely on antibody-based capture of CTCs, which express epithelial cell surface markers that are absent from normal leucocytes. Among these, epithelial cell adhesion molecule (EpCAM) is most commonly used. Although this platform is the most standardized of any current technology, it suffers from relatively low sensitivity. Survivin is a member of the inhibitor of apoptosis protein gene family that is highly expressed in most cancers. Several studies have shown the prognostic value of survivin in various malignancies, including lung cancer. But the diagnostic significance of survivin for non-small cell lung cancer (NSCLC) remains controversial. The purpose of this prospective study was to evaluate the diagnostic value of survivin-expressing CTCs in peripheral blood of patients with NSCLC.
Methods:
Blood samples were collected from patients with NSCLC before treatment and healthy volunteers. The EpCAM- and survivin- expressing CTCs were detected by real-time quantitative PCR.
Results:
To date, 43 patients with NSCLC stages I-IV and 15 healthy controls, all aged 52-79 years were enrolled in the study. Survivin mRNA was detected in the CTCs. Survivin- expressing CTCs were upregulated with more than 2-fold difference as compared with controls (p=0.004). EpCAM was not significantly different between NSCLC patients and controls (p=0.409). No correlation between the survivin-expressing CTCs levels and the stage of disease and histology can be made at this point.
Conclusion:
We demonstrated the significant difference in the levels of survivin-expressing CTCs between NSCLC patients and controls. These results suggest that survivin might be useful molecular marker for CTCs.
